Explore Biodesix’s Fair Values from the Community and select yours
It’s been a pretty great week for Biodesix, Inc. (NASDAQ:BDSX) shareholders, with its shares surging 10% to US$0.40 in the week since its latest second-quarter results. The results don’t look great, especially considering that statutory losses grew 17% toUS$0.08 per share. Revenues of US$20,018,000 did beat expectations by 8.4%, but it looks like a bit of a cold comfort. Earnings are an important time for investors, as they can track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. We’ve gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the current consensus from Biodesix’s six analysts is for revenues of US$82.7m in 2025. This would reflect a solid 8.0% increase on its revenue over the past 12 months. Losses are expected to increase slightly, to US$0.29 per share. Before this latest report, the consensus had been expecting revenues of US$82.0m and US$0.24 per share in losses. While this year’s revenue estimates held steady, there was also a notable increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock.
View our latest analysis for Biodesix
With the increase in forecast losses for next year, it’s perhaps no surprise to see that the average price target dipped 38% to US$1.80, with the analysts signalling that growing losses would be a definite concern. There’s another way to think about price targets though, and that’s to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Biodesix at US$2.00 per share, while the most bearish prices it at US$1.50. The narrow spread of estimates could suggest that the business’ future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It’s clear from the latest estimates that Biodesix’s rate of growth is expected to accelerate meaningfully, with the forecast 17% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 10% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.0% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Biodesix to grow faster than the wider industry.
